This report compares medication use in long-term care facilities and community settings for Medicare beneficiaries with heart conditions. The purpose of this comparison was to evaluate the utility of a new file of institutional drug use in the Medicare Current Beneficiary Survey (MCBS), the premier source of health care information on the Medicare population.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 131 - 140 of 145. 10 per page. Page 14.
Advanced SearchMedication Use in Long-Term Care Facilities and Community Settings for Medicare Beneficiaries with Cardiovascular Disease
December 17, 2002
The Contribution of Medication Use to Recent Trends in Old-Age Functioning
July 31, 2002
U.S. Department of Health and Human Services
Securing the Benefits of Medical Innovation for Seniors: The Role of Prescription Drugs and Drug Coverage
June 30, 2002
This report examines the consequences to medical innovation and overall health posed by attempts to contain drug expenditures by implementing government controls.
The Effects of Congressional Proposals on Prescription Drug Costs for Medicare Beneficiaries
June 18, 2002
Department of Health and Human Services Office of the Assistant Secretary for Public Affairs Provides discussion and estimates of several Congressional proposals on prescription drug costs for Medicare beneficiaries.
Medication Use by Medicare Beneficiaries Living in Nursing Homes and Assisted Living Facilities
June 4, 2002
This report compares the medication use of Medicare beneficiaries living in nursing homes and assisted living facilities. Descriptions of Medicare use include mean number of drug mentions per month of stay (scheduled and PRN drugs), and prevalence and duration of therapy by major drug classes.
Effects of Congressional Proposals on Prescription Drug Costs for Medicare Beneficiaries
May 31, 2002
Provides discussion and estimates of several Congressional proposals on prescription drug costs for Medicare beneficiaries.
The Graying of Medicare's Disabled Population: Implication for a Medicare Drug Benefit
February 28, 2002
U.S. Department of Health and Human Services
Price Trends for Prescription: Pharmaceuticals: 1995-1999
August 8, 2000
by Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University* A background report prepared for the Department of health and Human Services' Conference on Pharmaceutical Pricing Practices, Utilization and Costs August 8-9, 2000
Cost Control for Prescription Drug Programs: Pharmacy Benefit Manager (PBM) Efforts, Effects, and Implications
August 8, 2000
by David H. Kreling, Ph.D., R.Ph. Sonderegger Research Center University of Wisconsin School of Pharmacy A background report prepared for the Department of Health and Human Services' Conference on Pharmaceutical Pricing Practices, Utilization and Costs August 8-9, 2000
Medicare+Choice: Payment and Service Areas
April 30, 2000
The Balanced Budget Act of 1997 included a number of changes to Medicare managed care. The newly created Medicare+Choice program differs from its predecessor with regard to payment policies, enrollment and disenrollment policies, and the types of plans that can contract to provide care to Medicare beneficiaries.